Bioengineered Chip Model for Magnetic-Nanoparticle-Driven Targeted Cancer Therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Magnetic drug targeting (MDT) faces clinical hurdles including magnetic field attenuation and lack of accurate disease models.
• Existing models fail to replicate the tumor microenvironment (TME) and cellular responses to magnetic stimuli.

Purpose of the Study:

• To develop a novel on-chip model for evaluating magnetic drug carriers (MDCs) in a physiologically relevant tumor microenvironment.
• To address limitations in current MDT research models, including animal and synthetic platforms.

Main Methods:

• A lithography-free fabrication method created a biomimetic breast TME model with MDA-MB-231 cells in hydrogel and HUVEC-lined microchannels.
• Chitosan-coated MDCs (10-20 nm) were tested for retention under varying magnetic fields and shear stress.
• Live/dead assays, immunocytochemistry, flow cytometry, and gene expression analysis assessed drug efficacy and cellular responses.

Main Results:

• The on-chip model successfully replicated TME conditions, enabling precise magnetic-field calibration for MDC targeting.
• Magnetically targeted drugs demonstrated dose-dependent effects, inducing apoptosis and reducing invasion markers.
• The system facilitated assessment of MDC retention against magnetic field strength and shear stress.

Conclusions:

• The developed bioengineered chip is a cost-effective, scalable, and biomimetic platform for MDT research.
• This novel system enables preclinical screening of anticancer therapies and facilitates optimization of magnetic targeting strategies.